Drugs / FRENLOSIRSEN
FRENLOSIRSEN
also known as
FRENLOSIRSEN SODIUM · ION-251 FREE ACID · ION-935918 · ION-935918 FREE ACID · ION-935918 SODIUM · ION251
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04398485 | Jan 2021 → Sep 2024 | plasma cell myeloma | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRENLOSIRSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650261 ↗ |
| Known as | FRENLOSIRSEN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650261 ↗ |
| Known as | ION-251 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650261 ↗ |
| Known as | ION-935918 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650261 ↗ |
| Known as | ION-935918 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650261 ↗ |
| Known as | ION-935918 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650261 ↗ |
| Known as | ION251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04398485 ↗ |
| Modality | Antisense oligonucleotide | “we test the effects of IRF4 antisense oligonucleotides (ASOs) and identify a lead agent for clinical development (ION251).” PMID 33476575 ↗ Jan 2021 |
| Route | Intravenous | “ION251 administered by IV infusion” NCT04398485 ↗ |